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 Duchenne and Becker muscular dystrophy (DBMD) are X-linked conditions due 
to mutations within the dystrophin gene that cause progressive muscle weakness, 
respiratory insufficiency, and cardiomyopathy in affected males. Approximately two-
thirds of women who have a son with DBMD are carriers of the condition. Carriers 
typically do not manifest muscular symptoms but are at risk for cardiac abnormalities 
such as dilated cardiomyopathies. The American Academy of Pediatrics (AAP) 
recommends that carriers of DBMD receive a complete cardiac evaluation by a 
cardiologist that includes an echocardiogram and electrocardiogram (EKG) with re-
evaluation every five years. According to a recent study33, as many as 35.6% of carriers 
are not adhering to the AAP recommendations despite having knowledge of their carrier 
status. Limited research has been conducted into the barriers that carriers face in 
accessing recommended cardiac screening. We surveyed 60 carriers of DBMD and 
conducted semi-structured telephone interviews with 11 carriers who in the last five years 
either had not seen a cardiologist, had an echocardiogram, or had an EKG to determine 
the perceived challenges that carriers face in obtaining appropriate cardiac care. From the 
interviews, seven major themes emerged: 1) a lack of awareness among healthcare 
providers about cardiac risks 2) a responsibility among carriers for self-education and 
self-advocacy 3) frustration with misinformation received 4) a lack of concern due to lack 
of family history and/or a perceived healthy lifestyle 5) a lack of information-sharing 
with other carriers in the family 6) a priority of the healthcare needs of family members  
v 
over personal healthcare needs and 7) a belief that conversations about carrier status 
should begin at a younger age. Increased awareness, health education regarding risks for 
carriers, and advocacy efforts are needed for healthcare providers and carriers in order to 
ensure that this entire population receives the cardiac care they need. 
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1.1 Molecular mechanism of disease 
Duchenne and Becker muscular dystrophy (DBMD) are neuromuscular disorders 
known as dystrophinopathies, caused by mutations within the dystrophin gene located on 
the X chromosome at Xp21.1 and inherited in an X-linked recessive fashion.1 Dystrophin 
is one of the largest known genes at 2.2 Mb and is comprised of 79 exons. The dystrophin 
gene contains three promoters: M, B, and P. The M promoter encodes for a rod-shaped 
dystrophin protein which is found primarily in skeletal and cardiac muscle. Small 
amounts of dystrophin are also found in nerve cells in the brain; however, the exact 
function of the protein in the brain is not entirely known. The B promoter is responsible 
for production of dystrophin in the brain while the P promoter produces dystrophin 
expressed specifically in Purkinje cells in the brain.2  
Dystrophin found in skeletal and cardiac muscle functions in the dystroglycan 
complex (DGC) to connect intracellular actin filaments at the N-terminus to 
glycoproteins of the sarcolemma at the C-terminus.  The DGC is a complex made up of 
integral membrane proteins as well as peripheral proteins that works to provide support 
for cardiac or skeletal muscle cells during contraction by connecting actin filaments to 
the extracellular matrix (ECM). Dystrophin functions to stabilize the plasma membrane 
by carrying signals from sarcolemma contractions to the ECM.2 A figure representation 
of the DGC and its associated proteins is shown in Figure 1.1.  
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Figure 1.1 The dystroglycan complex2 
 
 
Due to its large size, the dystrophin gene is highly susceptible to mutations. 
Different types of muscular dystrophies arise from mutations within the dystrophin 
protein or within any of the other DGC-associated proteins. Exonic deletions comprise 
65% of all dystrophin mutations. Meanwhile, exonic duplications represent up to 10% of 
all dystrophin mutations. Both exonic duplications and deletions are traditionally detected 
previously by PCR analysis and more recently, by MLPA and aCGH analysis.3 Exonic 
duplications and deletions tend to be present at “hot spots” within the gene located in 
exons 45-53 which ultimately result in a frameshift. Small mutations such as nonsense 
and missense mutations, microdeletions, splice site mutations, and insertions make up the 
remaining 25-30%. These small mutations are undetectable by PCR but can be detected 
using techniques such as Sanger sequencing and next generation sequencing (NGS). 
Point mutations are not bound by hot spots and have been observed to be randomly 
distributed across the whole dystrophin gene. However, missense mutations have been 
found mostly at the N and C-termini.4 A lack of functional dystrophin due to a mutation 
compromises the membranes of the skeletal and cardiac muscle cells, and the cells are at 
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an increased risk for stress-induced damage from contraction. A damaged plasma 
membrane leads to an increase in calcium entering into the cell which results in cell death 
and the resulting phenotypic muscle weakness and wasting.2 
1.2 Duchenne muscular dystrophy (DMD) 
Affecting between 1 in 3802 to 1 in 6291 boys in the United States, DMD is a 
progressive muscle-wasting disorder.5 DMD is the most severe of the childhood muscular 
dystrophies.1 Over 1000 mutations have been identified in the dystrophin gene that are 
responsible for causing DMD with a penetrance of 100%.6 Pathogenic mutations in DMD 
cause a lack of dystrophin protein production which in turn cause severe, early-onset 
symptoms in DMD.7  
Clinically, absent dystrophin protein can present initially as motor delays and 
hypotonia.8 Calf pseudohypertrophy, Gower maneuver, and toe walking or an abnormal 
gait will present between the ages of two and five.9 As the disorder progresses, the risk 
increases to develop additional symptoms such as attention deficit hyperactivity disorder, 
autism, and obsessive-compulsive disorder suggesting a potential effect on 
neurocognitive function. Not much is known about the role of dystrophin in 
neurocognitive disorders; however, dystrophin is suspected to work closely with Purkinje 
fibers in the brain. In fact, approximately one-third of those diagnosed with DMD will 
experience a cerebellar function-related disorder like dyslexia, mild intellectual disability, 
or impairment in verbal working memory or in performing motor tasks.10 Additionally, 
because this is a progressive disorder, most boys with DMD will be wheelchair-bound by 
the age of twelve. Scoliosis and respiratory insufficiency are common with increasing 
age.  
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Cardiac involvement is present in almost all individuals with DMD. These cardiac 
abnormalities can include dilated cardiomyopathy and arrhythmia. Heart muscle wasting 
is the cause of dilated cardiomyopathy which usually begins in the left ventricle and 
occurs when the cardiac muscle thins and is unable to pump adequate amounts of blood 
to the body. Myocardial fibrosis is also associated with dysfunction with the left ventricle 
and is one of the most common histological signs of heart failure.11,12 Cardiac 
involvement often presents at approximately ten years of age and will affect almost all 
boys after age 18. Pre-clinical detection is possible through electrocardiograph and 
echocardiograph findings. Due to low physical activity with increasing age, most boys 
are relatively asymptomatic in regard to cardiac manifestation.13 However, if no steroid 
therapy is administered, death typically occurs in the early twenties due to congestive 
heart failure and can be predicted by the level of progressing respiratory insufficiency.14 
1.3 Becker muscular dystrophy (BMD) 
Becker muscular dystrophy is less frequent in the U.S. population than DMD and 
generally has milder symptoms. Compared to DMD, the mutations that result in BMD 
keep the transcript within the reading frame causing a protein that is abnormal or present 
in reduced amount instead of completely absent.7 Boys with BMD will typically present 
later in childhood around age twelve with limb girdle weakness and calf hypertrophy. 
However, BMD is a variable disorder. Some individuals present with muscle weakness 
later in life into mid to late adulthood, and some reported variants only cause weakness in 
the quadriceps or weakness as the result of exercise. Cognition is generally not impaired 
in cases of BMD. Individuals with BMD will generally remain ambulant much longer 
than those with DMD but are also at an increased risk for cardiomyopathy.14 
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Additionally, death does not usually occur until the fourth or the fifth decade of life. 
Cardiomyopathy is often the cause of death in both DMD and BMD.7  
1.4 Current management strategies 
There is currently no cure for muscular dystrophy. Those with muscular 
dystrophy require a multidisciplinary team to manage their symptoms including yearly 
visits to neurologists, cardiologists, pulmonologists, physical and occupational therapists, 
and nutritionists.14 Glucocorticosteroids are often the course of treatment used to 
maintain muscle strength and slow muscle wasting in addition to maintaining lung 
function, prolonging ambulation, and reducing the incidence of scoliosis.15 The two most 
common corticosteroids implemented are prednisone and deflazacort, also known as 
Emflaza. Mechanisms by which these corticosteroids ameliorate muscular dystrophy 
symptoms are not completely understood. However, it is known that prednisone acts in 
an anti-inflammatory way to increase skeletal muscle force. Deflazacort functions to 
regenerate and differentiate muscle cells.16 As of 2017, deflazacort was FDA-approved in 
patients over the age of 5 with DMD, making it the second drug to be approved for 
treatment  
Orthopedic surgery is often recommended in managing DMD or BMD. Special 
consideration must be given to those individuals who undergo surgery as they are at an 
increased risk for complications related to lung and cardiac function. In order to maintain 
cardiac function, lung function must be maintained as well. Appropriately functioning 




1.5 New treatments 
Several therapeutic modalities are being investigated as potential treatments for 
patients with muscular dystrophy. Exon-skipping is one potential therapy for muscular 
dystrophy patients. Data suggests that up to 80% of DMD could be amenable to exon-
skipping therapies. Currently in clinical trials, these drugs allow for skipping of mutated 
exons in the pre-mRNA to produce a more truncated form of dystrophin and minimize 
the effects of the mutation.16 The only FDA-approved exon-skipping drug, eteplirsen, 
functions in skipping of exon 51, in which 13% of DMD cases will have a mutation. 
Drugs designed for skipping of exons 44, 52, 50, 43, 55, 8 and 35 are currently in 
preclinical trials.  
Gene therapy, another potential treatment, uses a virus to deliver a functioning 
dystrophin gene to cardiac and skeletal muscle cells in order to produce functioning 
dystrophin protein. Because of its large size, the dystrophin gene is unable to fit inside a 
traditionally used adeno-associated virus (AAV). Thus, a truncated dystrophin gene is 
created so as to produce a Becker-like phenotype in the receiving individual. However, 
the current challenge includes an adverse immune response from the host.16 Several gene 
therapy trials are ongoing for DMD. Notably, in January of 2018, Dr. Mendell and his 
team at Nationwide Children’s Hospital, delivered the first dose using a systemic 
microdystrophin gene therapy. Gene therapy promises to be a potential avenue for 
muscular dystrophy treatment.  
Gene editing has also recently surfaced. One specific genome editing tool, 
CRISPR/Cas9, provides much potential for curative muscular dystrophy treatment. 
CRISPR/Cas 9 makes use of a guide RNA to target a specific location in the genome and 
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allows for insertion of a functioning dystrophin gene due to naturally-occurring DNA 
repair mechanisms. Due to potential off-target effects as well as ethical dilemmas 
surrounding the editing of the human genome, CRIPR/Cas9 is still in the pre-clinical 
phase of development.16 
Currently in clinical trials, stem cell therapy offers the potential for stem cells 
which are able to differentiate into any cell type, to regenerate damaged muscle cells in 
muscular dystrophy patients.16 
1.6 Health risks in carriers of DBMD 
Because muscular dystrophy is caused by a mutation on the X chromosome, 
males are generally affected while females are carriers. According to Davie and Emery,17 
one third of muscular dystrophy cases are caused by a de novo mutation, and the 
remaining two-thirds of cases are inherited from a mother who is a carrier. One study18 of 
mothers of sons with muscular dystrophy found the carrier frequency for DMD to be 58% 
and the carrier frequency of BMD to be about 90%. Importantly, carriers of DMD and 
BMD are at increased risk for specific health concerns.  
Penetrance of symptoms is variable in female carriers, and the spectrum of 
symptoms is wide. Carriers of DMD are generally more severely affected than carriers of 
BMD.19 One study20 determined that up to 7.8% of female carriers are symptomatic with 
muscle wasting, myalgia, or muscle cramps. These symptoms had a variable onset 
between the ages of 2 and 47 years old. While some carriers exhibited a severe DMD-like 
phenotype, others had adult-onset, less severe symptoms.  
A study done in the Netherlands by Hoogerwaard et al.7 similarly found that 19% 
of DMD female carriers and 16% of BMD female carriers exhibited muscle weakness. 
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When cardiac abnormalities were taken into consideration, 22% of carriers exhibited 
some symptoms of muscular dystrophy. 
A possible explanation for selective female carriers experiencing symptoms could 
be due to skewed X-inactivation (XCI). XCI is the process by which females undergo 
dosage equalization of the X chromosome. Most females in the general population have a 
random pattern of inactivation and thus are mosaic for maternal and paternal X 
chromosomes. A non-random XCI pattern could be one explanation for a manifesting 
carrier and may even explain age of onset of symptoms as well as severity. However, 
there is still a lack of absolute correlation between a muscular dystrophy phenotype in 
female carriers and non-random XCI. In fact, Soltanzadeh et al.19 found in their study of 
13 manifesting carriers that only five carriers exhibited nonrandom X-inactivation (38%) 
which is consistent with other reports suggesting that skewed XCI cannot be the only 
explanation for symptoms in manifesting carriers. More research is needed in this area to 
determine the impact of X-inactivation on manifesting female carriers.21,22 Genetic 
modifiers may be another factor influencing the manifestation of symptoms in carriers. 
Genetic modifiers in DMD have been shown to affect age of onset of symptoms, affected 
muscle groups, disease progression, and disease severity.23  
1.7 Cardiac risk in carriers of DBMD 
Most female carriers do not show any outward symptoms of muscular dystrophy. 
However, carriers may exhibit a wide range of cardiac abnormalities ranging from mild 
findings on echocardiogram to hypertrophic abnormalities, left ventricular dilation 
(which can be considered the precursor to dilated cardiomyopathy), and dilated 
cardiomyopathies.24,25 These cardiac issues pose serious health threats to carriers and in 
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some cases require a transplant or can even result in death.26 Approximately 60% of 
DMD and BMD carriers have cardiac abnormalities25 with one study27 finding dilated 
cardiomyopathies in approximately 10.9% of carriers. Dilated cardiomyopathies have the 
potential to develop heart failure—requiring heart transplantation. Another study7 of 129 
Dutch carriers found that 8% of carriers of DMD displayed dilated cardiomyopathy with 
an additional 18% of both DMD and BMD carriers presenting with dilation of the left 
ventricle on echocardiogram and no presenting muscle weakness. Soltanzadeh and 
colleagues19 determined in a study of 13 manifesting carriers that 38% exhibited 
decreased systolic function on echocardiogram. In a study24 of 36 carriers utilizing 
cardiac magnetic resonance imaging (MRI), myocardial damage and fibrosis were 
present in 44% of carriers. Yet another study27 of 197 female carriers found that 
preclinical or clinically-detected myocardial anomalies were found in 84.3% of cases of 
DMD and BMD carriers. Furthermore, the significance of cardiac involvement increased 
with age with 54.5% of carriers aged 5 to 16 years old experiencing cardiac involvement 
and 90.2% in those older than 16 years. Significant cardiac disease is not common in 
those under 16 years of age. Cardiomyopathies tend to develop in the fourth or fifth 
decade of life and progress slowly.21  
One study conducted by McCaffrey et al.28 found that carriers showed 
abnormalities on cardiac MRI 3-33% of the time depending upon the definition of 
cardiomyopathy and different measurements such as left ventricular fractional shortening 
and left ventricular ejection fraction. Based on echocardiogram, they found that 7-13% 
exhibited significant systolic dysfunction. They additionally found that cardiomyopathy 
in all cases was not associated with mutation type, DMD vs. BMD phenotype, creatine 
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kinase level, the presence of muscle symptoms, or even age. All of the subjects in this 
study were asymptomatic—reporting no intolerance to exercise, breathlessness, 
arrhythmias, or cardiac failure.  
1.8 Surveillance recommendations for DBMD carriers 
According to the American Academy of Pediatrics Section on Cardiology and 
Cardiac Surgery published in 2005,1 carriers should be made aware of their risk for 
cardiomyopathy and educated on the signs of heart failure. Additionally, they should be 
referred to a cardiac specialist for a complete cardiac evaluation in late adolescence or 
early adulthood—including a history and physical examination, electrocardiogram 
(EKG), and a transthoracic echocardiogram. Re-evaluation with a cardiologist should 
occur every five years beginning between the ages of 25 and 30. Treatment of 
cardiomyopathy in carriers is similar to treatment for individuals with DBMD as outlined 
in the American Academy of Pediatrics (AAP) guidelines. 
While echocardiogram is the current screening standard for cardiomyopathy, 
cardiac MRI is increasingly becoming the preferred method of screening used by 
cardiologists. Cardiac MRI, also known as cardiovascular magnetic resonance (CMR) is 
a tool used to detect myocardial fibrosis, a sign of cardiomyopathy. The use of cardiac 
MRI could detect subtle pathologies of the myocardium in the event of a normal 
echocardiograph evaluation. Cardiac MRI is increasingly becoming a preferred screening 
tool to identify patients at increased risk of cardiac abnormalities and to identify those 
patients that should begin treatment so as to delay the progression of the cardiomyopathy. 
A study conducted by Mavrogeni et al.29 determined that up to 66% of carriers will 
present with an abnormal finding detected by CMR whereas only 17% of those carriers 
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would present with an abnormal echocardiogram.24 A recent study30 performed on a 
small group of 15 carriers found that all DMD carriers exhibited cardiac abnormalities 
when screened with cardiac MRI. 
Treatment for cardiomyopathy in carriers is similar to the treatment of 
cardiomyopathy in patients with DBMD.1 Guidelines for management of patients with 
cardiomyopathies recommend implementation of drugs such as angiotensin converting 
enzyme inhibitors or beta-blockers.31 ACE inhibitors prevent the conversion of 
angiotensin I to angiotensin II which ultimately lowers artery resistance, increases venous 
capacity, increases cardiac output and index, increases stroke volume, and increases 
natriuresis. Beta-blockers bind to beta-adrenoceptors in order to block norepinephrine 
and epinephrine from binding. This reduces stimulation of heart rate, contractility, 
electrical conduction, and relaxation rate.32 
1.9 Adherence to surveillance recommendations among carriers 
According to recent research, female carriers of DMD or BMD may not be 
adhering to the recommendations outlined by the AAP. One study33 found that of 833 
carriers, 35.6% of them had never had a cardiac evaluation despite knowing their carrier 
status. A similar study26 of 137 known carriers and 45 of unknown status found that only 
45.5% of confirmed female carriers had had an echocardiogram in the last five years with 
21% of them never having had an echocardiogram. While known carriers were twice as 
likely to have had an echocardiogram in the last five years than those of unknown status, 
having a son recently diagnosed with muscular dystrophy had no significant effect on 
whether or not an echocardiogram was performed recently. 
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Many factors could contribute to a lack of adherence to the AAP 
recommendations in carriers. According to Bobo et al.33 69% of female carriers stated 
that their healthcare providers were aware that they were a carrier of DBMD. Those 
carriers that had an informed healthcare provider were significantly more likely to have 
had a cardiac evaluation when compared with those women whose healthcare providers 
were not aware of their carrier status. This study found that certain factors increased a 
carrier’s likelihood of having a heart test including being over the age of 49, having a 
female relative with heart disease, having awareness of their cardiomyopathy risk, and 
having an informed healthcare provider.   
Bobo and colleagues33 also found that cost was a factor that inhibited women 
from participating in cardiac surveillance. In addition, having no symptoms of heart 
disease, receiving no recommendations from a healthcare provider, having no awareness 
of cardiac risks, and having no muscle weakness were all reasons for not pursuing cardiac 
screening. This study found that 37.1% of carriers had never heard or read about their 
increased risk for cardiomyopathy in the past which suggests that a lack of knowledge of 
associated cardiac risk is a potential barrier.   
Many carriers of DBMD who are aware of their carrier status do not seem to be 
following self-care recommendations regarding cardiac surveillance as detailed by the 
AAP even though up to one in ten may experience overt cardiac failure.34 Various factors 
may contribute to challenges experienced by this population in obtaining appropriate 
cardiac surveillance including: 
1) Carriers may have received inadequate and insufficient education at the time 
that they were informed of their carrier status. 
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2) If the individual’s carrier status was revealed at the same time period in which 
her son was diagnosed with muscular dystrophy, her own diagnosis could have 
been overshadowed by the information of her son’s diagnosis. 
3) Carriers may refrain from cardiac surveillance because of a perceived low risk 
of developing a cardiomyopathy. This may be because she is unaware of the 
severity of cardiomyopathies, because she has other female carrier relatives who 
have not developed symptoms or are also not adhering to the recommendations, 
or again, because of a lack of education. 
4) Some carriers may have limited access to healthcare. Socioeconomic status, 
accessibility to a vehicle, time it takes to get to the appointment, availability of the 
cardiologist, and other healthcare disparities potentially factor into healthcare 
access.  
5) Caring for a son with muscular dystrophy has taken precedence over the 
carrier’s own health. Studies have shown that those who take the role of a 
caregiver experience stress, distress, high caregiving demands, and are more 
likely to have psychological effects related to the caregiving.35 
Hypothesis 
Various barriers may inhibit female carriers of DBMD from obtaining appropriate 
cardiac surveillance. Lack of education, perceived low cardiomyopathy risk, lack of 
accessibility to a cardiologist, burden of being a caregiver for an affected son or sons, or a 
combination of factors may contribute to poor adherence to the AAP recommendations in 
female carriers. In order to identify the specific barriers that female carriers experience, 
this study will explore three specific aims:  
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1) Assess the experience of female carriers at their initial discovery of their carrier 
status. 
 2) Determine the specific cardiac care practices that female carriers are following 
or not following. 
3) Identify perceived challenges and barriers to appropriate cardiac care. 
By making an effort to understand the needs of this patient population, healthcare 
professionals may be able to better address specific concerns that this population is facing 
in obtaining appropriate cardiac self-care. This presents as an opportunity for genetic 
counselors to become more aware of the needs of this population themselves but also to 
raise awareness and to advocate for this population that may be underserved. Through 
one-on-one interviews, this study aims to evaluate the barriers to self-care that carriers of 
DMD or BMD are experiencing. This is primarily an exploratory study, and its goal is to 
provide insight into a population to highlight unique areas of concern or unmet needs that 





ASSESSING THE BARRIERS TO CARDIAC CARE IN CARRIERS OF 
DUCHENNE AND BECKER MUSCULAR DYSTROPHY1 
2.1 Abstract 
Purpose: Duchenne and Becker muscular dystrophy (DBMD) are X-linked conditions 
causing progressive muscle weakness, respiratory insufficiency, and cardiomyopathy in 
affected males. Approximately two-thirds of women who have a son with DBMD are 
heterozygote carriers of the condition. Carriers typically do not manifest muscular 
symptoms but up to 60%25 are at risk for cardiac abnormalities with one study27 finding 
10% of DBMD carriers with development of dilated cardiomyopathy. The American 
Academy of Pediatrics (AAP) recommends that carriers of DBMD receive a complete 
cardiac evaluation by a cardiologist between age 25 and 30 that includes echocardiogram 
and electrocardiogram with re-evaluation every five years. Recent studies33 suggest as 
many as 35.6% of carriers are not adhering to that five-year recommendation despite 
having knowledge of their carrier status. Limited research has been conducted into the 
barriers that carriers of DBMD face in accessing recommended cardiac screening. 
Methods: Participants completed a short questionnaire to identify carriers who were and 
were not following the AAP recommendations. Semi-structured telephone interviews 
were offered to 11 carriers of DBMD who in the last five years had not seen a   
                                                          
1 Eekhoff, L., Edwards, J., Martin, A., & Prijoles, E. To be submitted to Journal of Family Practice 
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cardiologist, had an echocardiogram, had an EKG, or a combination to determine the 
perceived challenges that carriers face in obtaining appropriate cardiac care. 
Results: Most carriers surveyed (71.7%, 43/60) reported adherence to appropriate cardiac 
care while 28.3% (17/60) of carriers in our study did not receive appropriate care. From 
the participants interviewed (11/17), seven major themes emerged as barriers to the 
receipt of cardiac care. These included a perception amongst carriers that healthcare 
providers lacked awareness of cardiac risks and associated recommendations. Carriers 
perceived a decreased risk for cardiac complications due to a perceived healthy lifestyle 
or lack of family history of cardiac events. Some carriers experienced a lack of 
information-sharing among family members. Carriers tended to place the healthcare 
needs of family members above their own. Carriers believed conversations about carrier 
status should begin at a younger age.  
Conclusions: This study called attention to the barriers of obtaining appropriate cardiac 
care among this population. Increased awareness and advocacy for this unique group is 
essential with the goal that all members of this population receive the cardiac care that 
they need.  
2.2 Introduction 
Duchenne and Becker muscular dystrophy (DMD and BMD) are neuromuscular 
disorders known as dystrophinopathies, caused by X-linked mutations within the 
dystrophin gene located at chromosome Xp21.1.1 Duchenne muscular dystrophy is the 
most severe of the childhood muscular dystrophies. Symptoms in childhood begin with 
muscle weakness and wasting that renders affected individuals non-ambulatory 
commonly by the age of 12.1,9 Dilated cardiomyopathies and arrhythmias typically are 
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found in individuals with DMD. In fact, death often occurs in the mid-20s due to cardiac 
events.14  
Becker muscular dystrophy is generally a less severe form of muscular dystrophy 
in which muscle weakness presents later in life.14 Affected individuals remain ambulatory 
longer and death occurs later—into the fourth and fifth decades. 
Two-thirds of DBMD are due to pathogenic variants on the X chromosome 
inherited from a female carrier.17 Carriers typically do not present with symptoms of 
muscle wasting; however, they are at increased risk for significant cardiac events 
including hypertrophic involvement, left ventricular dilation, and 
cardiomyopathy.19,20,24,25,27 One group34 estimates that approximately 10% of DBMD 
carriers will develop overt cardiac failure.  
Cardiac disease poses serious health threats to carriers and in some cases requires 
a transplant or can result in death.26 In a study of 129 carriers, Hoogerward et al.25 found 
that approximately 60% of muscular dystrophy carriers experienced cardiac 
abnormalities detected by echocardiogram. Of these, 8% of cardiac abnormalities were 
dilated cardiomyopathies. In a study24 of 36 carriers utilizing cardiac MRI, myocardial 
damage and fibrosis were detected in 44% of carriers. Yet another study27 of 197 female 
carriers found that preclinical or clinically-detected myocardial anomalies were found in 
84.3% of cases of DMD and BMD carriers. Furthermore, the significance of preclinical 
or clinically evident cardiac involvement increased with age with 54.5% of carriers aged 
5 to 16 years old experiencing cardiac involvement and 90.2% in those older than 16 
years. Thus, the possibility of cardiac events in carriers of DBMD is evident, and the 
cardiac care needs of this population must be consistently addressed. 
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The American Academy of Pediatrics (AAP) recommends carriers of DBMD be 
referred to a cardiac specialist for a complete cardiac evaluation at the time of diagnosis. 
Subsequent evaluations should occur every five years beginning between the ages of 25 
and 30. These evaluations should include EKG, echocardiogram, and consideration for a 
cardiac MRI.1 Evidence suggests that carriers of muscular dystrophy may not be adhering 
to the AAP recommendations. Bobo et al.33 found that of 833 carriers, 35.6% had never 
had an echocardiogram despite being aware of their carrier status. A similar study26 of 
182 women published in 2016 found that only 45.5% of confirmed carriers had had an 
echocardiogram in the past five years. 
To identify the specific barriers to receiving cardiac care that carriers of DBMD 
experience, this study aimed to: 1) Determine the specific cardiac care practices that 
carriers are and are not following 2) Identify perceived challenges and barriers to 
appropriate cardiac care in this unique population at risk for cardiac disease. 
2.3 Materials and Methods 
Participants 
Women over the age of 18 were eligible to participate in this study if they had a 
family history indicating their carrier status or if they had completed genetic testing 
confirming they were a carrier of DBMD. Carrier status was based upon self-reported 
data. The University of South Carolina Institutional Review Board reviewed the protocol 
and designated it as exempt from review.  
Instrumentation 
A 10-item questionnaire was distributed via a web link (See Appendix A) that 
was sent in an email to over 500 registrants of DuchenneConnect, an online registry for 
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individuals with Duchenne and Becker muscular dystrophy and carrier females in the 
United States. The study information and questionnaire link were emailed twice. These 
were first distributed to registered manifesting carriers or confirmed carriers and then to 
DBMD registrants who reported that their mother was a carrier. The questionnaire 
assessed: a) Knowledge and confirmation of the participant’s own carrier status and b) 
Personal screening history for cardiac risks. Additionally, the participants could provide 
contact information if they wished to be contacted for a semi-structured telephone 
interview. Eligible for the interview were those participants who had not had an EKG, 
echocardiogram or cardiac MRI in the past five years, or seen a cardiologist in the past 
five years. 
Telephone interviews included questions about participants’ initial discovery of 
their carrier status, current healthcare services received, and challenges they perceived in 
obtaining appropriate cardiac care (see Appendix B for interview questions). All 
interviews were recorded using either VoiceRecorder or RecordPad Sound Recorder and 
were saved on the researcher’s private computer under password protection.  
Data analysis 
The researcher transcribed all interviews. All transcripts were analyzed for themes 
using grounded theory data analysis. Interviews were separately reviewed and coded 
independently by the author and a research assistant. Kappa coefficient was calculated at 
0.68. Quantitative data was described by counting response types and through descriptive 
statistics (percentages and means). All identified themes and representative quotes can be 





Sixty individuals registered with DuchenneConnect completed the online 
questionnaire. Forty-three individuals (43/60, 71.7%) received appropriate cardiac care as 
evidenced by self-reported receipt of an echocardiogram, EKG, and a visit with a 
cardiologist within the past five years. Seventeen individuals (17/60, 28.3%) either had 
not been seen by a cardiologist, had an EKG, or had an echocardiogram in the past five 
years. Three of these individuals did not provide contact information for a telephone 
interview. An additional three individuals were unable to be contacted for an interview. 
Telephone interviews were conducted with eleven individuals. Interviews lasted between 
22 and 51 minutes (median 28 minutes). 
Many carriers interviewed (9/11) were Caucasian. The majority of carriers 
worked outside the home (7/11). Education level ranged from completion of high school 
to doctorate level, master’s degree, and law degree. The majority (9/11) lived in an urban 
area. Figure 2.1 indicates states represented by participants interviewed. The two 
participants from Texas were not related to one another. No participants stated relation to 




Figure 2.1 States represented by carriers interviewed (n=11). Two carriers  
interviewed were from Texas.  
 
Most carriers (10/11) had had confirmatory genetic testing with one individual 
determined to be an obligate carrier based on the pattern of inheritance from her family 
history. 
Much variability existed in the specific cardiac screens that each participant had 
and had not undertaken. Figure 2.2 represents the specific screenings that the carriers 





Figure 2.2 Adherence to cardiac screenings among carriers 
interviewed based upon AAP recommendations (n=11) 
 
Participants interviewed ranged in age from 28 to 70 with a mean age of 40 years. 
Figure 2.3 demonstrates the age at which each participant discovered they were a carrier 
compared to their age at the time of the interview. An average of 12 years elapsed since 
participants’ discovery of carrier status and the time interviewed representing the amount 




Figure 2.3 Amount of time between participants’ discovery of carrier status and age at 
present (n=11) 
 
 Many carriers (8/11) had a living son with muscular dystrophy, and most of those 
individuals (6/8) reported discovering their carrier status while their son was diagnosed 
with muscular dystrophy.  Most carriers (7/10) recalled meeting with a genetic counselor 
who explained the testing and the results; however, only 5/10 recalled the associated 
cardiac risks being discussed with them. Notably, even though all carriers interviewed 
had a primary care physician who was aware of their carrier status, the majority (8/11) 
were unfamiliar with the AAP recommendations for cardiac screening.  Additional 







Table 2.1 Background information of carriers interviewed (n=11) 
 
 
Several themes emerged from analysis of the interview transcripts. Each theme is 
illustrated by verbatim quotes from the interview transcripts. 
Theme 1: Carriers experienced a lack of awareness regarding cardiac risks among 
healthcare providers. 
This most common theme identified was discussed by all carriers interviewed. 
Carriers reported a lack of understanding among primary healthcare physicians and 
cardiologists about muscular dystrophy, carriers of muscular dystrophy, and associated 
cardiac risks. Carriers most often cited among cardiologists that there was an 
unfamiliarity with the necessity of cardiac screening for carriers. Carriers often felt like 
they were responsible for educating their healthcare providers about symptoms associated 




Do you have a son with muscular 
dystrophy? 8 3
Did you discover your carrier status 
upon your son's diagnosis? 6 2 3
Do your son's doctors ever discuss 
your carrier status? 2 5 4
Were you referred for a complete 
cardiac evaluation at the time of 
diagnosis of carrier status? 5 6
Are you aware of the AAP 
recommendations? 3 8




…the PCP was like, “Well why are you here?” type of thing. And 
so…basically the PCPs have no clue about, you know, Duchenne or any of 
those muscular dystrophy types. 
 
I saw a cardiologist here locally…he had no idea why I was there. It was 
completely useless. Giant waste of time.  
Additionally, some healthcare providers may not be familiar with the AAP 
recommendations. Some patients (6/11) reported that upon discovery of their carrier 
status, they were not referred by their healthcare provider for an initial cardiac evaluation 
as per the AAP recommendations. Many reported receiving misinformation regarding the 
necessity of frequent examinations.  
After I had my first one [cardiac evaluation], they told me, “Your heart is 
healthy…There’s no reason for you to ever come back.”  
 
So I took my daughter to see the cardiologist, and the cardiologist 
dismissed my concerns and said, “You’re done. Graduate.” And that was 
that. 
Theme 2: Carriers were responsible for educating themselves about risks associated 
with being a carrier; carriers were their own advocates. 
Despite all carriers reporting that their primary healthcare physician (PCP) was 
aware of their carrier status (11/11), the majority reported that their PCP did not discuss 
cardiac risks or remind them to have cardiac screenings. Often this left carriers on their 
own and forced them to seek out appropriate care independently. 
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You’re kind of left with it on your own.  I had to take initiative with 
organizing cardiology appointments. And my doctor won’t get on me to 
remind me to do it because he has no real expertise in that area. When I 
had my Holter monitor test, I was telling everything to my doctor about my 
carrier status, and he was on the computer looking it up.  
 
I do have to be the one that asks for these tests. Like [my PCP]…is not like 
monitoring it. It’s more if I bring it up.  
Carriers reported often turning to sources outside healthcare professionals such as 
the internet or other carriers to receive information about their carrier status. Many 
acknowledged a frustration with the lack of resources and information and a desire for a 
more easily accessible and reliable source for information for carriers.  
Just like looking it up and just hearing from other people that are carriers 
as well and not too much detail just kind of word of mouth from what 
everyone else was saying. So there’s not too much on the internet about it, 
so just from hearing from other…moms that are carriers as well.  
Carriers reported the added challenge of working with a healthcare professional 
who is unaware of a condition, its associated risks, and recommendations for screening. 
They reported the burden and difficulty of being a self-advocate for their condition.   
I think also you kind of need that permission to do [cardiac screenings]. 
You know like if your doctor’s saying you have to go do X, Y, Z you’re 
going to do it. It’s a lot harder to go out of your way to say, “You know 
what, I need to do. I need a screening.”  
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Theme 3: Carriers were frustrated with the misinformation they had received 
regarding cardiac risks and wished to be educated about associated risks. 
Carriers reported being unaware of specific risks and recommendations associated 
with their carrier status. The majority were unfamiliar with the AAP recommendations 
(8/11). For some, this lack of personal awareness was frustrating.  
…it really bothers me. [The AAP recommendations] is something I should 
have known or been doing all along…maybe it would have answered some 
questions I had or could explain what was going on with me…or knowing 
that it was something if I could have caught ahead of time maybe I could 
have done something about it.  
Carriers reported a desire for more information specifically about symptoms to be 
aware of, the nuances of the different heart screening tests, and what a risk for 
cardiomyopathy truly means. Despite the desire to be educated about cardiac risks, many 
carriers discussed the difficulty in obtaining information about carriers of DBMD. They 
reported obtaining information regarding cardiac risks from a variety of sources including 
the internet, family members, or other carriers. Oftentimes, this information was not 
accurate and was presented that carrier status only affects family planning decisions and 
future pregnancies. 
I just also remember like it being communicated to me from [my father] 
that it doesn’t affect that many carriers and it’s not something you need to 
worry about until you’re older. 
Misinformation included being unaware of the benefit of a cardiac evaluation, a 
misunderstanding of the mechanism of cardiac risks, and the exact risks associated with 
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being a carrier. In some cases, this misinformation resulted in a lack of concern for 
associated cardiac risks.  
I don’t really feel like I’m very educated on…what to expect as a carrier, 
what to be mindful of. 
Theme 4: Carriers were unconcerned about cardiac risks due to perceived healthy 
lifestyles or a lack of a family history of cardiac events. 
Many participants pointed to a lack of family history of cardiac events in other 
family members who were carriers as evidence of their lack of concern for cardiac risks. 
Even those who had a history of cardiac events were unconcerned because no healthcare 
provider had ever associated muscular dystrophy with the history of cardiac events.  
I also talked to my mom and she said well our family history—which we 
know quite well—we don’t seem to have that cardiac complication…her 
mom died of cancer at an advanced age. Her mom who was the sister of 
the…great-great uncles who would’ve had Duchenne, she lived deep into 
her nineties, had no cardiac trouble. Her mom didn’t have a cardiac 
problem either so we figured we were ok to not really bother. 
A perceived active and healthy lifestyle including frequent exercise and eating a 
healthy diet was also cited as a reason for less concern for cardiac complications in 
carriers.  






Theme 5: Some carriers experienced a lack of openness and information-sharing 
with other family members who were also carriers. 
When asked about the amount of information-sharing amongst other carriers in 
the family, some participants (4/9) reported that they do not discuss their carrier status or 
cardiac care with other family members, specifically family members who are or are at 
risk to be carriers of DBMD. Many reported being unsure as to whether those family 
members received the recommended cardiac screenings. Some reported that the lack of 
openness was due to feelings of guilt associated with passing on the mutation within the 
family. 
It’s kind of a touchy subject, an upsetting subject, because if [my mother] 
ever found out she was the cause of everything, it would be very upsetting. 
Other reasons for a lack of openness among family members included religious 
beliefs and a lack of apparent symptoms amongst other family members that would 
otherwise be cause for concern.  
There’s this strange notion that…amongst their family that…God had 
punished them somehow by giving them this..it’s just like something they 
just never talk about. I think it’s just too painful for my mom’s family so 
I’m a little nervous or shy about bringing it up. 
Theme 6: Carriers tended to put the needs of their family members before their own 
healthcare needs. 
The majority of carriers interviewed (8/11) reported having a living son with 
muscular dystrophy. For some participants (3/11), this meant staying in the home full-
time to provide care for their son. They reported that caregiving for a child with medical 
 
30 
needs takes a significant amount of time and energy. Often their own healthcare needs 
took less precedence to the needs of their children.  
I’m the last person to think of myself. You know there’s so many other 
things I have to do and the life schedule of living with kids with special 
needs is hardcore. It is…not easy to find the time to breathe let alone the 
time to say I should take care of myself… 
 
I’m usually seeing the doctor like when I’m at the end of the rope.   
Theme 7: Carriers believed conversations about carrier status and associated risks 
should begin at an earlier age. 
Participants believed that conversations about carriers and risks should begin at a 
young age, and information should include more than reproductive-planning and 
recurrence risks. Some carriers (5/11) recalled at their initial diagnosis that the 
information delivered was focused on reproductive recurrence risk with little mention of 
the potential physical symptoms associated with being a carrier.  
And it would totally change lives sometimes for the better, sometimes for 
the worse, but for very different if these girls understood from the very 
young age… 
Carriers acknowledged that often the healthcare needs of those affected with 
muscular dystrophy became a priority of healthcare professionals and caregivers so that 
carriers felt more or less forgotten.  
Carriers matter and carriers have symptoms…it’s not necessarily the 
muscles, and our life expectancies may indeed be comparable to other 
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people, but we have some serious needs that would help our lives so much 
to be addressed.  
2.5 Discussion 
This interview-based qualitative study explored the barriers to adherence to the 
AAP recommendations for cardiac screening amongst carriers of Duchenne and Becker 
muscular dystrophy. Our screening questionnaire identified that 71.7% (43/60) carriers 
received appropriate cardiac screening as outlined by the AAP recommendations. This 
number is higher than was found in two previous studies of carriers of DBMD; one 
study33 determined that 64.4% of known carriers had ever had a cardiac evaluation, and a 
similar study26 found that 45.5% of carriers surveyed had had an echocardiogram in the 
past five years. The high proportion of carriers in our study that were adhering to the 
AAP recommendations indicated that the majority of carriers within the 
DuchenneConnect population are informed of the recommendations and are being 
appropriately screened by cardiologists. This high percentage may be due to a number of 
factors. The homogenous group of study participants taken from the DuchenneConnect 
Registry may have increased access to educational materials through the website and 
email service provided by the Registry and Parent Project Muscular Dystrophy (PPMD), 
the advocacy organization that funds the Registry. Both the DuchenneConnect Registry 
and PPMD may also provide a platform for increased support and accountability from 
other members to stay up-to-date on cardiac screenings. Additional research is needed to 
understand the reasons why and how this population is receiving information and is 
motivated to adhere to the recommendations.   
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 Despite the finding that the majority of carriers surveyed received appropriate 
cardiac care, the focus of this study was on the 28.3% (17/60) who did not adhere to the 
AAP recommendations. The lack of adherence to the recommendations amongst the 
minority poses a serious healthcare risk to these carriers. Those risks include an increased 
likelihood to develop cardiac abnormalities including cardiomyopathy which could result 
in premature death if left undetected and untreated. Previous research26,33 has found that 
possible reasons for a lack of adherence to the AAP recommendations among DBMD 
carriers may include factors like lack of personal awareness of cardiac risk, having an 
uninformed healthcare provider, knowledge of carrier status, and cost.  
A number of barriers to accessing cardiac care were identified from the interviews 
with the eleven carriers in this study. The major theme recognized was a perceived lack 
of awareness of associated cardiac risks and screening recommendations displayed by 
cardiologists, primary care physicians, and other healthcare providers. Carriers 
experienced frustration with healthcare professionals who displayed lack of awareness, 
resources, and information for carriers. More education efforts may be needed to ensure 
that healthcare providers are aware of the increased risk for cardiac abnormalities in 
carriers, of the AAP recommendations, and of appropriate sources for referral.  
Carriers were identified as self-advocates and were responsible for self-education 
regarding their carrier status and associated risks. Frustration with misinformation 
received and with lack of accessible information available to them was recurrent. A 
thorough and clear explanation of DBMD carrier status including potential symptoms and 
risks associated with being a carrier is of utmost importance upon initial diagnosis. Initial 
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counseling about the diagnosis should encompass cardiac care for carriers in addition to 
reproductive risks.  
Healthcare providers are in a position to point carriers to appropriate sources of 
information so that they are informed of cardiac risks and are empowered to seek 
appropriate care. Many healthcare providers including cardiologists, neurologists, 
pulmonologists, nutritionists, genetic counselors, and many more specialties are involved 
in the care of a child with muscular dystrophy. A responsibility of healthcare providers 
involved on this multidisciplinary team in a muscular dystrophy clinic involves 
recognizing not only the needs of the child affected with Duchenne or Becker muscular 
dystrophy, but also his mother who is a potential carrier. A unique opportunity exists for 
healthcare providers to share appropriate resources and information for mothers who are 
carriers. This may include educational pamphlets or reputable internet sources. One such 
online resource is PPMD, (www.parentprojectmd.org) and their DuchenneConnect 
Registry (www.duchenneconnect.org). The PPMD website provides information on care, 
research, and advocacy including detailed information for DBMD carriers. DBMD 
carriers are also encouraged to join the DuchenneConnect Registry.  
A lack of family history of cardiac events and a perceived healthy lifestyle may 
also act as a barrier to receiving cardiac care for some carriers. It is unclear the extent that 
cardiac abnormalities affect carriers in different families. The lack of family history of 
cardiac events should not be considered evidence of a decreased risk for an abnormality. 
Even carriers without a family history of cardiac events among carriers should adhere to 
the AAP recommendations. The AAP recommends that all carriers require periodic 
cardiac screening with the rationale that the risk for developing cardiac disease is present 
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“irrespective of skeletal muscle disease.”1 Inherited cardiomyopathy cannot be prevented; 
however, carriers should be encouraged to follow healthy lifestyle practices such as 
frequent exercise and a balanced, heart-healthy diet.  
Lack of communication within a family amongst carriers may more easily foster a 
lack of adherence to AAP recommendations. Previous research has identified that having 
a female family member with heart disease increased the likelihood of personal receipt of 
a cardiac test.33 Without other family members as a resource for information and 
accountability, it is important that carriers receive appropriate and accurate information 
from their healthcare providers regarding necessity and timing of cardiac screenings. 
Genetic counselors are equipped through their specific training to navigate the difficulty 
of closed familial relationships and feelings of guilt within a family as well as to address 
information regarding risks to carriers, the genetic mechanism of disease, and recurrence 
risks. Recognition of need and identification of referrals to other specialists like genetic 
counselors may be appropriate in the care of carriers of DBMD.  
Carriers may put the healthcare needs of their sons with muscular dystrophy over 
their own healthcare needs. This is not a unique finding to this population. In fact, 
previous studies36 have shown that caregivers of children with a chronic condition have a 
significantly lower health-related quality of life which includes areas such as cognitive 
functioning, sleep, social functioning, daily activities, vitality, and positive and 
depressive emotions than parents who are not caregivers of a chronically-ill child. 
Healthcare professionals have the responsibility to emphasize to carriers the importance 
of adherence to the cardiac care recommendations of the AAP. Beyond that, healthcare 
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professionals must recognize the burden of caregiving experienced by an individual and 
should be prepared to offer support.  
Carriers desired that conversations about their carrier status begin at an earlier age 
and include more than information regarding reproductive recurrence risk. Genetic 
testing of a minor may act as a barrier to determination of carrier status until a potential 
carrier reaches the age of 18; however, many healthcare providers and families are now 
open to carrier testing of children under the age of 18. Communication within the family 
unit about carriers and their associated risks should be encouraged by healthcare 
providers.     
This study offered insight into the challenges that carriers of DBMD faced in 
obtaining recommended cardiac care. As indicated by the carriers interviewed in this 
study, the most significant barrier to obtaining cardiac care was a perceived lack of 
education and awareness experienced among healthcare providers. The goal of this study 
was to call attention to the needs of this population and to provide education for those 
medical professionals who serve them. We hope that this study will be valuable to the 
healthcare community and will prompt personal evaluation, and a potential adjustment of 
practice, of each individual provider’s interaction with members of this unique 
population. Increased awareness and advocacy efforts are necessary until the entire 
group, that is carriers of Duchenne and Becker muscular dystrophy, is able to receive 
appropriate cardiac care.  
Limitations 
Study participants were registrants of DuchenneConnect and thus this study 
surveyed a small proportion of carriers of DBMD who are actively seeking information 
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through this organization. Sixty carriers completed the survey of the over five hundred 
registrants to whom the survey was sent. The majority of our participants were Caucasian 
and highly educated. Findings from this study were specific to participants interviewed 
and cannot be generalized to the larger population of carriers of muscular dystrophy.   
Future research 
 Future research may include an exploration of the different sources of information 
provided to carriers and their efficacy in prompting cardiac screening. Additionally, 
future research should target a larger, more heterogenous group of carriers to determine 
more accurately the specific barriers to obtaining appropriate cardiac care experienced. 
Further, more research is warranted into the significant majority of carriers identified in 
this study that are receiving appropriate cardiac care. This may include more in-depth 
research into the specific information individuals have received regarding carrier status, 
associated risks, and patient resources.  
Conclusions 
A significant number of DBMD carriers received appropriate cardiac care based 
upon the AAP recommendations. A perceived lack of education and awareness among 
healthcare providers was a barrier most often reported by carriers who were not receiving 
appropriate cardiac care. Increased educational and awareness efforts are needed among 
healthcare providers and carriers about DBMD to promote increased adherence to cardiac 







Carriers of Duchenne and Becker muscular dystrophy are at increased risk for 
cardiac complications including cardiomyopathy. Previous research has found that some 
carriers may not be adhering to the AAP recommendations that state that every five 
years, carriers should be seen by a cardiologist and receive an EKG and echocardiogram.  
This study found that 71.7% of carriers surveyed received appropriate cardiac 
care. Of the 28.3% who did not receive recommended care, several themes were 
identified that represented barriers to obtaining appropriate care. The most common 
theme discussed was a perceived lack of awareness among healthcare providers and 
available resources for carriers.  
Healthcare providers including primary care physicians, cardiologists, genetic 
counselors, and all those involved in the care of carriers of DBMD have the responsibility 
to be well-informed regarding the needs of this population. Carriers as well as healthcare 
providers can work together to promote increased awareness and advocacy so as to 
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 This is a research project being conducted by Lauren Eekhoff at the University of 
South Carolina in Columbia, SC. The purpose of this research project is to identify the 
challenges that women who are known to be carriers of Duchenne or Becker Muscular 
Dystrophy (DBMD) experience in obtaining cardiac surveillance. You are invited to take 
this questionnaire if you have a living or deceased son with Duchenne or Becker 
Muscular Dystrophy and you have been found to be a carrier. 
 
This study contains two parts: 1) a 10-minute questionnaire intended to determine 
if you are a carrier of DBMD 2) a 30-minute phone interview in which you will be asked 
questions regarding the specific challenges that you experience in obtaining cardiac care. 
This is the main focus and vital piece of the study, and if you would be willing to 
participate in an interview, there will be a designated location at the end of the 
questionnaire where you can provide your contact information. Your responses will be 
kept confidential. The results of this study will be used for scholarly purposes only. 
 
Your participation in this research study is voluntary. You may choose not to 
participate. If you decide to participate in this research study, you may withdraw at any 
time. If you decide not to participate in this study or if you withdraw from participating at 
any time, you will not be penalized. 
 
Please complete this questionnaire only once. If you do not reach the “Thank you 
for completing the survey” page at the end, your responses may not be included in the 
final analysis. 
 
*1. Clicking on the "agree" button below indicates that:  
 
• you have read the above information 
• you voluntarily agree to participate 
• you are at least 18 years of age  
 
If you do not wish to participate in the research study, please decline participation by 
clicking on the "disagree" button. 
  
2. Check the box next to the one statement that applies to you: 
I have a living son (or sons) with Duchenne or Becker Muscular Dystrophy
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I no longer have any living sons with Duchenne or Becker Muscular Dystrophy 
I have never had any sons with Duchenne or Becker Muscular Dystrophy 
 
3. Check the box next to the statement that best describes you: 
I know my carrier status, and I am a Duchenne or Becker Muscular Dystrophy carrier 
I know my carrier status, and I am not a Duchenne or Becker Muscular Dystrophy 
carrier 
I do not know my carrier status 
I am not sure what this question is asking 
 
4. How did you confirm your carrier status? Select all that apply. 
I had genetic testing 
I had a blood test but I am not sure if it was genetic testing 
I am an obligate carrier (meaning that my carrier status is certain based on the pattern 
of      affected boys in my family) 
A physician told me 
A genetic counselor told me 
I am not sure 
Other method (please specify) 
 
5. Please tell us the most recent time (month and year) you... 
…saw a cardiologist 
…had an ECG (test that checks the heart rhythm) 
…had an echocardiogram or cardiac MRI (tests that look at the heart) 
 




Two or more 
 
7. Mark the statement which is most true for you and your extended family. In choices B 
and C, consider “my son” to mean your first affected son if you have had more than one 
son with Duchenne or Becker. 
a. My son (or sons) is the only person in the family with Duchenne or Becker. 
b. My son was the only person in the family with Duchenne or Becker at the time he 
was diagnosed, but since then, at least one other family member (not another son of my 
own) has been diagnosed with Duchenne or Becker Muscular Dystrophy 
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c. My son was not the first person in the family to be diagnosed with Duchenne or 
Becker; there was a family history of the condition prior to my pregnancy with my son. 
d. I am not sure / none of these seem true for my family 
 
8. This study includes an interview conducted via phone call that will last approximately 
30-40 minutes. Your participation is greatly appreciated and your responses invaluable to 
this study. Would you be willing to participate in the interview portion of this study?  
o Yes 
o No 
9. Please provide your preferred contact information so that we may contact you to set up 
the interview for this study. Your contact information will not be linked to your 












Carrier Status Discovery (Educational Barrier) 
1. Tell me about the time when you discovered you were a carrier of muscular 
dystrophy. 
a. When? (How many years ago was this?) 
b. How old were you? 
c. Was this the same time that your son was diagnosed? 
d. Who informed you of your carrier status? 
e. What information did you receive during that diagnosis? How was it 
explained to you? 
f. Do you feel that the information you received was sufficient at that time or 
were you left with questions? 
g. Do you know who to contact if you do have questions? 
h. Were you referred for a complete cardiac evaluation at that time of 
diagnosis? 
 
Self-care Current Practices (Perceived Risk Barrier) 
1. Are you aware of any health risks associated with being a carrier of MD? 
2. How concerned are you with the health risks associated with being a carrier? 
3. Are you aware of the American Academy of Pediatrics’ recommendations for 
carriers of MD? (cardiac eval every 5 years) 
a. How important is it to you to follow the AAP recommendations for 
cardiac evaluation? 
b. Have you ever been seen by a cardiologist? 
c. When was the last time you had an ECG and/or an echocardiogram? A 
cardiac MRI? 
 
Barriers/Challenges (Relationship with healthcare provider, lack of support, access to 
healthcare, emotional burden, denial? Barriers) 
1. What are your reasons for having (not having) an ECG and/or echocardiogram? 
2. Tell me about your relationship with your primary healthcare provider. 
a. Is he/she aware of your carrier status? 
b. How frequently do you discuss your carrier status/associated health risks? 
3. Do you have any other females in your family that have had genetic testing and 
are carriers of muscular dystrophy? 
a. What is your relationship like with them? 





4. Tell me about your access to cardiac care/a cardiologist. 
a. Is it easy for you to get to your appointments? 
b. How long does it take you to get to a cardiologist? 
c. What is your relationship like with your cardiologist? 
d. Do you feel comfortable asking him/her any questions you may have? 
5. Tell me about being a mother of a child with a condition like muscular dystrophy.  
a. Do you attend all his healthcare appointments with him? 
b. Do any of the specialists ever discuss your own cardiac health issues? 
c. Many mothers have to balance their family’s health care need with taking 
care of their own health care needs. Oftentimes, mom’s healthcare needs 
get put on the back-burner. How is this for you? 
6. Tell me about the routine healthcare screenings you partake in annually. 
a. When was your last mammogram, colonoscopy, physical, etc.? 
 
7. The ultimate goal of this study is to raise awareness of healthcare professionals 
about the needs of carriers of DBMD. What do you want your cardiologist, 
genetic counselor, etc. to know about your healthcare needs? Is there any way you 
can think that would help us serve you better?   
 
Demographics 
8. What is your age? 
9. What is your ethnicity? 
10. What is your race?  
11. What is your current occupation? 
12. What is the highest level of education you have completed?  





















MAJOR THEMES AND REPRESENTATIVE QUOTES 
 
Carriers experience a lack of 
awareness regarding cardiac risks 
among healthcare providers in 
general.
Carriers are responsible for 
educating themselves about risks 
associated with being a carrier and 
are their own advocates.
Carriers are frustrated with the 
misinformation regarding cardiac 
risks.
Anyway they’re not familiar around 
here with this disease where I live.
You know I didn’t know about that 
[increased cardiac risks], and actually 
she [my mother] didn’t know about 
that until I did research. I got really 
curious about it, and I wanted to know, 
you know, all about it and about being 
a carrier and all that.
When they say I’m a carrier and there’s 
a risk for cardiomyopathy like what does 
that really mean? Like is it because of the 
amount of deletion genes that I’m 
missing? Like yeah I think it’s just 
understanding that more and being more 
aware of that.
 I guess they’ve felt like you know an 
EKG and then a Holter monitor worn 
for twenty-four hours was was enough 
to give them you know the information 
they needed.
It’s more for myself initiating it 
[cardiologist appointments].
I’d like to be educated on uhm perhaps 
specifically what tests should be done 
every five years. That was like big news 
to me that you told me that. Uhm and I 
would say uhm like what symptoms to 
look out for in general. Uhm and in 
terms of cardiac uhm and also be to 
being aware of uhm the appropriate 
resources that I can do to get more 
information or more support.
I don’t know how to deal with 
physicians cuz like I said you’ve got 
some physicians that test you and 
they’re way proactive and look things 
up and then you’ve got other 
physicians who deal with it all the 
time... And you kinda have to tell them 
what the recommendation is.
When I make an appointment again I’m 
going to make sure that I have my 
son’s doctor, Shanti’s doctor, write 
something down or I don’t know find 
something electronic to my cardiologist 
to let them know why I’m coming in 
for testing. Or I guess it’s like people 
aren’t familiar with it.
How it was framed it was like, “This 
isn’t an issue until you decide to have 
children,” which I think is like generally 
true uhm but I kinda wish with that there 
had been a little bit more of 
conversation.
Each cardiologist is like, “I have no 
idea why you’re here.”  And I explain 
to them because of muscular 
dystrophy if I’m a carrier that means I 
may have cardiomyopathy I think it is 
and then something with my kidneys. 
Yep and both of them had no idea 
what I was talking about.
Where I found out about uhm what 
carrier care I needed was from the 
MDA website.
Do cardiologists actually see people like 





Carriers are unconcerned about cardiac 
risks due to perceived healthy lifestyles 
or a lack of a family history of cardiac 
events.
Some carriers experience a lack of 
openness with other family 
members who are also carriers.
Carriers tend to put the needs 
of their family members 
before their own healthcare 
needs.
Carriers believe conversations about 
carrier status and associated risks should 
begin at an earlier age.
I’m not too worried about it. Uhm I don’t 
have any like. With my mom being a carrier, 
she’s never even had. Actually after she 
found out she’s a carrier, they did a workup 
on her heart. She’s never had any problems 
so I’m really not worried about it.
And I think if my mom found out she 
was a carrier it probably would be 
devastating for her. That’s why in the 
very beginning I never said you should 
get tested too.
So how much time do we spend 
caregiving? 24/7 yeah. And 
that’s that’s really both my 
husband and me spending 
essentially all of our time 
caregiving for these adorable 
kids who absolutely deserve it.
If my mother had knew [about my carrier 
status] and she had explained it to me when I 
was growing up and everything that might 
have saved me a lot of always being a 
mystery every time I went to the doctor about 
you know what was going on with my body 
and all that.
She [my mother] didn’t have any real 
cardiac you know. And so my grandmother 
who would’ve been a carrier didn’t have 
any you know cardiac issues….I felt like 
because of the family history that I’m not 
really at risk for it.
I think it was hard for her [my mother] 
to talk about so she never said 
anything.
I was trying to work a job. I was 
trying to take care of him. I 
never had time for myself. I 
never had time to take myself to 
the doctor. I never had time to 
uhm to really care for myself.
They will not allow us to test for her [my 
daughter] because she’s not of age of 
consent until she turns 18 and I was a little bit 
upset about that but you know I was like well 
I’m not saying that she would but say if she 
would get pregnant at 13, I would like to 
know so that I can educate my daughter.
It’s just like in our family like I mean yeah 
there’s been heart issues but like nothing’s 
been directly linked to muscular dystrophy. 
So like it’s never really concerned me.
I feel like my dad is able to talk more 
about it. I will say like there is a part of 
me that feels uhm like hesitant or kinda 
shy away from bringing it up with him 
uhm I think because there’s this 
dynamic of both my parents were in 
healthcare and I think they adopted 
this, “Unless you’re seriously sick 
you’re totally fine.”
Things like that where something 
is like you know I have an injury 
or something. I’m kinda like, 
“Eh whatever. I’ll wait until it 
gets worse or whatever.” Cuz I 
mainly want him and my 
daughter like their whatever their 
appointments and their stuff first 
and I’ll deal with myself later.
I try to eat you know well and everything. I 
exercise at least 4 to 5 times a week. At 
least I’m exercising and things like that. So 
you know just try to keep myself healthy as 
possible.
She [mom] thinks all this is her fault. 
She doesn’t understand the genetics 
and I explained to her the science and 
the genetics, “This is not your 
fault.”...they don’t understand that and 
neither do her sisters
